Guanidyl-rich highly branched poly(β-amino ester)s for the delivery of dual CRISPR ribonucleoprotein for efficient large DNA fragment deletion
Xianqing Wang,
No information about this author
Yinhao Li,
No information about this author
Dana Friess
No information about this author
et al.
Journal of Controlled Release,
Journal Year:
2025,
Volume and Issue:
379, P. 549 - 557
Published: Jan. 24, 2025
Language: Английский
Breaking barriers: Smart vaccine platforms for cancer immunomodulation
Cancer Communications,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 3, 2025
Abstract
Despite
significant
advancements
in
cancer
treatment,
current
therapies
often
fail
to
completely
eradicate
malignant
cells.
This
shortfall
underscores
the
urgent
need
explore
alternative
approaches
such
as
vaccines.
Leveraging
immune
system's
natural
ability
target
and
kill
cells
holds
great
therapeutic
potential.
However,
development
of
vaccines
is
hindered
by
several
challenges,
including
low
stability,
inadequate
response
activation,
immunosuppressive
tumor
microenvironment,
which
limit
their
efficacy.
Recent
progress
various
fields,
click
chemistry,
nanotechnology,
exosome
engineering,
neoantigen
design,
offer
innovative
solutions
these
challenges.
These
achievements
have
led
emergence
smart
vaccine
platforms
(SVPs),
integrate
protective
carriers
for
messenger
ribonucleic
acid
(mRNA)
with
functionalization
strategies
optimize
targeted
delivery.
Click
chemistry
further
enhances
SVP
performance
improving
encapsulation
mRNA
antigens
facilitating
precise
delivery
review
highlights
latest
developments
technologies
therapy,
exploring
both
opportunities
challenges
advancing
transformative
approaches.
Language: Английский
Engineering Folic Acid‐Modified Nanoparticles to Enhance Letrozole's Anticancer Action
Neda Rostami,
No information about this author
Abuzar Nikzad,
No information about this author
Shervin Shaybani
No information about this author
et al.
Macromolecular Bioscience,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 18, 2025
Abstract
The
development
of
biodegradable
nanoparticles
(NPs)
for
delivering
anticancer
drugs,
such
as
letrozole
(LTZ),
offers
a
targeted
approach
cancer
therapy.
In
this
study,
we
synthesized
poly(ε‐caprolactone)‐
co
‐poly(ethylene
glycol)
(PCL‐
‐PEG)
and
fabricated
LTZ‐loaded
PCL‐
‐PEG
NPs
(LTZ‐NPs)
via
emulsion‐solvent
evaporation.
Folic
acid
(FA),
folate
receptor‐targeting
molecule,
was
conjugated
to
the
(LTZ‐FNPs)
enhance
treatment
efficacy
against
hormone
receptor‐positive
breast
cells.
Both
FNPs
exhibited
spherical
morphology
(60–90
nm),
with
showing
higher
drug
entrapment
efficiency
controlled
release.
LTZ
release
minimal
at
physiological
pH
but
increased
in
acidic,
cancer‐like
environments,
following
Korsmeyer‐Peppas
model,
indicating
combination
Fickian
non‐Fickian
diffusion.
cytotoxicity
assays,
LTZ‐FNPs
toxicity
MCF‐7
cells
than
LTZ‐NPs.
Controlled
altered
gene
expression,
reducing
B‐cell
leukemia/lymphoma
2
protein
(Bcl2)
increasing
caspase
8
(Casp8),
promoting
apoptosis.
A
shift
SubG1
phase
further
confirmed
enhanced
LTZ‐FNP‐mediated
cell
death.
Furthermore,
p53
expression
increased,
while
matrix
metalloproteinase
9
(MMP‐9)
decreased,
inhibiting
invasion.
This
study
introduces
system
FA‐functionalized,
pH‐sensitive
delivery
LTZ.
holds
great
potential
selective,
efficient
minimizing
systemic
Language: Английский
Nanogene editing drug delivery systems in the treatment of liver fibrosis
Qun Wang,
No information about this author
Siyu Jia,
No information about this author
Zihan Wang
No information about this author
et al.
Frontiers in Medicine,
Journal Year:
2024,
Volume and Issue:
11
Published: Sept. 25, 2024
Liver
fibrosis
is
a
group
of
diseases
that
seriously
affect
the
health
world’s
population.
Despite
significant
progress
in
understanding
mechanisms
liver
fibrogenesis,
technologies
and
drugs
used
to
treat
have
limited
efficacy.
As
revolutionary
genetic
tool,
gene
editing
technology
brings
new
hope
for
treating
fibrosis.
Combining
nano-delivery
systems
with
tools
achieve
precise
delivery
efficient
expression
can
be
has
become
rapidly
developing
field.
This
review
provides
comprehensive
overview
principles
methods
commonly
targets
We
also
discuss
recent
advances
common
vehicles
formulations
research.
Although
potential
advantages
fibrosis,
it
still
faces
some
challenges
regarding
efficiency,
specificity,
safety.
Future
studies
need
address
these
issues
further
explore
application
Language: Английский
Advances in CRISPR-Cas technology and its applications: revolutionising precision medicine
Sarkar Sardar Azeez,
No information about this author
Rahin Shareef Hamad,
No information about this author
Bahra Kakamin Hamad
No information about this author
et al.
Frontiers in Genome Editing,
Journal Year:
2024,
Volume and Issue:
6
Published: Dec. 12, 2024
CRISPR-Cas
(Clustered
Regularly
Interspaced
Short
Palindromic
Repeats-CRISPR-associated
proteins)
has
undergone
marked
advancements
since
its
discovery
as
an
adaptive
immune
system
in
bacteria
and
archaea,
emerged
a
potent
gene-editing
tool
after
the
successful
engineering
of
synthetic
guide
RNA
(sgRNA)
toward
targeting
specific
DNA
sequences
with
high
accuracy.
Besides
editing
ability,
further-developed
Cas
variants
can
also
edit
epigenome,
rendering
versatile
for
genome
epigenome
manipulation
pioneering
force
precision
medicine.
This
review
explores
latest
technology
therapeutic
biomedical
applications,
highlighting
transformative
impact
on
Moreover,
current
status
CRISPR
therapeutics
clinical
trials
is
discussed.
Finally,
we
address
persisting
challenges
prospects
technology.
Language: Английский